Clinical Trial Update: Camostat With Bicalutamide for COVID-19 [Phase 1]

View source ↗

Summary

Phase 1 trial of camostat with bicalutamide for COVID-19 was terminated; results were posted in 2023.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Coronavirus Infection
• Sars-cov Infection

Drugs mentioned

• Camostat (camostat mesylate)
• bicalutamide (bicalutamide)

Snippet

Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Conditions: Covid19, SARS-CoV Infection | Phase 1 | Status: TERMINATED | Results posted: 2023-10-06